• Oncotelic Therapeutics entered a securities purchase agreement with Pacific Pier Capital II for a USD 178,410 convertible promissory note.
• The note carries a 12% original issue discount, pays 12% annual interest, and matures in one year unless earlier accelerated or prepaid.
• Pacific Pier can convert at USD 0.06 per share or 85% of the lowest traded price over the prior 10 trading days.
• Oncotelic issued 500,000 common shares as commitment shares; default interest rises to 16% if an event of default occurs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncotelic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-031124), on June 29, 2026, and is solely responsible for the information contained therein.